Somatostatin secretion by Na


Journal

Nature metabolism
ISSN: 2522-5812
Titre abrégé: Nat Metab
Pays: Germany
ID NLM: 101736592

Informations de publication

Date de publication:
01 2020
Historique:
entrez: 30 1 2020
pubmed: 30 1 2020
medline: 30 1 2020
Statut: ppublish

Résumé

Pancreatic islets are complex micro-organs consisting of at least three different cell types: glucagon-secreting α-, insulin-producing β- and somatostatin-releasing δ-cells

Identifiants

pubmed: 31993555
doi: 10.1038/s42255-019-0158-0
pmc: PMC6986923
mid: EMS85189
pii: 10.1038/s42255-019-0158-0
doi:

Substances chimiques

Insulin 0
Somatostatin 51110-01-1
Glucagon 9007-92-5
Sodium 9NEZ333N27
Glucose IY9XDZ35W2
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

32-40

Subventions

Organisme : Medical Research Council
ID : MR/T002107/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106262
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106263/Z/14/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0801995
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 201325/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/5
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12012/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/3
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 095531/Z/11/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 201325
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12012/5
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 084210
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 095531
Pays : United Kingdom
Organisme : Diabetes UK
ID : 12/0004622
Pays : United Kingdom

Déclaration de conflit d'intérêts

Competing interests The authors have no competing interests.

Références

Dolensek, J., Rupnik, M. S. & Stozer, A. Structural similarities and differences between the human and the mouse pancreas. Islets 7, e1024405 (2015).
doi: 10.1080/19382014.2015.1024405
Hauge-Evans, A. C. et al. Somatostatin secreted by islet δ-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 58, 403–411 (2009).
doi: 10.2337/db08-0792
Yue, J. T. et al. Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats. Diabetes 61, 197–207 (2012).
doi: 10.2337/db11-0690
Cryer, P. E. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes 54, 3592–3601 (2005).
doi: 10.2337/diabetes.54.12.3592
Rorsman, P. & Huising, M. O. The somatostatin-secreting pancreatic δ-cell in health and disease. Nat. Rev. Endocrinol. 14, 404–414 (2018).
doi: 10.1038/s41574-018-0020-6
Caduff, A. et al. Dynamics of blood electrolytes in repeated hyper- and/or hypoglycaemic events in patients with type 1 diabetes. Diabetologia 54, 2678–2689 (2011).
doi: 10.1007/s00125-011-2210-9
Adriaenssens, A. E. et al. Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets. Diabetologia 59, 2156–2165 (2016).
doi: 10.1007/s00125-016-4033-1
Zhang, Q. et al. R-type Ca(2+)-channel-evoked CICR regulates glucose-induced somatostatin secretion. Nat. Cell Biol. 9, 453–460 (2007).
doi: 10.1038/ncb1563
Trube, G., Rorsman, P. & Ohno-Shosaku, T. Opposite effects of tolbutamide and diazoxide on the ATP-dependent K
doi: 10.1007/BF00657506
Vergari, E. et al. Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion. Nat. Commun. 10, 139 (2019).
doi: 10.1038/s41467-018-08193-8
van der Meulen, T. et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21, 769–776 (2015).
doi: 10.1038/nm.3872
Zhang, Q. et al. Role of K
doi: 10.1016/j.cmet.2013.10.014
Briant, L. J. B. et al. δ-cells and β-cells are electrically coupled and regulate ɑ-cell activity via somatostatin. J. Physiol. 596, 197–215 (2018).
doi: 10.1113/JP274581
Wright, E. M., Loo, D. D. & Hirayama, B. A. Biology of human sodium glucose transporters. Physiol. Rev. 91, 733–794 (2011).
doi: 10.1152/physrev.00055.2009
Henquin, J. C. & Meissner, H. P. The electrogenic sodium-potassium pump of mouse pancreatic B-cells. J. Physiol. 332, 529–552 (1982).
doi: 10.1113/jphysiol.1982.sp014429
Unwin, R. J., Luft, F. C. & Shirley, D. G. Pathophysiology and management of hypokalemia: a clinical perspective. Nat. Rev. Nephrol. 7, 75–84 (2011).
doi: 10.1038/nrneph.2010.175
Denwood, G. et al. Glucose stimulates somatostatin secretion in pancreatic delta-cells by cAMP-dependent intracellular Ca(2+) release. J. Gen. Physiol. 151, 1094–1115 (2019).
doi: 10.1085/jgp.201912351
Rosengren, A. H. et al. Reduced insulin exocytosis in human pancreatic β-cells with gene variants linked to type 2 diabetes. Diabetes 61, 1726–1733 (2012).
doi: 10.2337/db11-1516
Knudsen, J. G. et al. Dysregulation of glucagon secretion by hyperglycemia-induced sodium-dependent reduction of ATP production. Cell Metab. 29, 430–442 e434 (2019).
doi: 10.1016/j.cmet.2018.10.003
Abdel-Halim, S. M., Guenifi, A., Efendic, S. & Ostenson, C. G. Both somatostatin and insulin responses to glucose are impaired in the perfused pancreas of the spontaneously noninsulin-dependent diabetic GK (Goto-Kakizaki) rats. Acta Physiol. Scand. 148, 219–226 (1993).
doi: 10.1111/j.1748-1716.1993.tb09551.x
Hermansen, K. Characterisation of the abnormal pancreatic D and A cell function in streptozotocin diabetic dogs: studies with D-glyceraldehyde, dihydroxyacetone, D-mannoheptulose, D-glucose, and L-arginine. Diabetologia 21, 489–494 (1981).
doi: 10.1007/BF00257791
Ghezzi, C., Loo, D. D. F. & Wright, E. M. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia 61, 2087–2097 (2018).
doi: 10.1007/s00125-018-4656-5
Kuhre, R. E. et al. No direct effect of SGLT2 activity on glucagon secretion. Diabetologia 62, 1011–1023 (2019).
doi: 10.1007/s00125-019-4849-6
Ghezzi, C. & Wright, E. M. Regulation of the human Na
doi: 10.1152/ajpcell.00115.2012
Bonner, C. et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med. 21, 512–517 (2015).
doi: 10.1038/nm.3828
Ferrannini, E. et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124, 499–508 (2014).
doi: 10.1172/JCI72227
Hawley, S. A. et al. The Na
doi: 10.2337/db16-0058
Hermansen, K., Lindskog, S. & Ahren, B. Stimulation of somatostatin secretion by 3-O-methylglucose in the perfused dog pancreas. Int. J. Pancreatol. 20, 103–107 (1996).
pubmed: 8968865
Rorsman, P., Ammala, C., Berggren, P. O., Bokvist, K. & Larsson, O. Cytoplasmic calcium transients due to single action-potentials and voltage-clamp depolarizations in mouse pancreatic B-cells. EMBO J. 11, 2877–2884 (1992).
doi: 10.1002/j.1460-2075.1992.tb05356.x
Palty, R. et al. NCLX is an essential component of mitochondrial Na
doi: 10.1073/pnas.0908099107
Chera, S. et al. Diabetes recovery by age-dependent conversion of pancreatic δ-cells into insulin producers. Nature 514, 503–507 (2014).
doi: 10.1038/nature13633
Adam, J. et al. Fumarate hydratase deletion in pancreatic β cells leads to progressive diabetes. Cell Rep. 20, 3135–3148 (2017).
doi: 10.1016/j.celrep.2017.08.093
Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101–1108 (2008).
doi: 10.1038/nprot.2008.73
Briant, L. J. B. et al. CPT1a-dependent long-chain fatty acid oxidation contributes to maintaining glucagon secretion from pancreatic islets. Cell Rep. 23, 3300–3311 (2018).
doi: 10.1016/j.celrep.2018.05.035

Auteurs

Elisa Vergari (E)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK.

Geoffrey Denwood (G)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK.

Albert Salehi (A)

Department of Neuroscience and Physiology, University of Göteborg, Göteborg, Sweden.
Department of Clinical Sciences Malmö, Clinical Research Centre, Malmö, Sweden.

Quan Zhang (Q)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK.

Julie Adam (J)

Nuffield Department of Clinical Medicine, University of Oxford, NDM Research Building, Oxford, UK.

Ahmed Alrifaiy (A)

Department of Neuroscience and Physiology, University of Göteborg, Göteborg, Sweden.

Ingrid Wernstedt Asterholm (I)

Department of Neuroscience and Physiology, University of Göteborg, Göteborg, Sweden.

Anna Benrick (A)

Department of Neuroscience and Physiology, University of Göteborg, Göteborg, Sweden.

Margarita V Chibalina (MV)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK.

Lena Eliasson (L)

Department of Clinical Sciences Malmö, Clinical Research Centre, Malmö, Sweden.

Claudia Guida (C)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK.

Thomas G Hill (TG)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK.

Alexander Hamilton (A)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK.
Department of Clinical Sciences Malmö, Clinical Research Centre, Malmö, Sweden.

Reshma Ramracheya (R)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK.

Frank Reimann (F)

MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Nils J G Rorsman (NJG)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK.

Ioannis Spilliotis (I)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK.
Oxford National Institute for Health Research, Biomedical Research Centre, Churchill Hospital, Oxford, UK.

Andrei I Tarasov (AI)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK.
Oxford National Institute for Health Research, Biomedical Research Centre, Churchill Hospital, Oxford, UK.

Jonathan N Walker (JN)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK.
MacLeod Diabetes and Endocrine Centre, Royal Devon and Exeter Hospital, Exeter, UK.

Patrik Rorsman (P)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK. patrik.rorsman@gu.se.
Department of Neuroscience and Physiology, University of Göteborg, Göteborg, Sweden. patrik.rorsman@gu.se.
Oxford National Institute for Health Research, Biomedical Research Centre, Churchill Hospital, Oxford, UK. patrik.rorsman@gu.se.

Linford J B Briant (LJB)

Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, Churchill Hospital, Oxford, UK. linford.briant@ocdem.ox.ac.uk.
Department of Computer Science, University of Oxford, Oxford, UK. linford.briant@ocdem.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH